title: Safety and efficacy of total dose infusion of 1,020 mg of ferumoxytol administered over 15 min.
abstract: For the majority of patients with iron deficiency anemia (IDA), a full course of intravenous (IV) iron is 1 g. Most IV irons require 5-10 administrations of 100-300 mg. We have successfully employed 1 g low molecular weight iron dextran over 1 hr. For further convenience for patients and physicians, we explored the administration of 1.02 g of ferumoxytol over 15 min instead of the approved 2 × 510 mg injections. Sixty patients with IDA, (hemoglobin <11 g/dL, transferrin saturation [TSAT] ≤20%, and ferritin <100 ng/mL) with an inadequate response or intolerance to oral iron, received 1020 mg ferumoxytol over 15 min. Vital signs were measured for 1 hr. Adverse events (AEs) were collected via telephone at 1, 2, and 7 days. Follow-up visits occurred at 4 and 8 weeks for efficacy assessments. The primary endpoint was safety and tolerability. Secondary efficacy endpoints included mean change in hemoglobin, TSAT, and red cell distribution width. No serious adverse events (SAEs) occurred. Fifty-eight patients received the planned dose. Twenty-six out of sixty (43.3%) patients reported AEs of which 13 were mild and transient during infusion. All resolved within minutes. Fourteen patients reported self-limited arthralgias, myalgias, and/or headache within 24-48 hr. At Baseline, the mean hemoglobin was 9.4 g/dL. The mean increments at Week 4 and 8 were 2.1 and 2.6 g/dL, respectively. Ferumoxytol, administered as 1.02 g infusion over 15 min was well tolerated with no SAEs and demonstrated excellent efficacy. If corroborated in future studies this represents an improved method of treating IDA.
authors.affiliation: Auerbach Hematology and Oncology, 9110 Philadelphia Road Suite 314, Baltimore, Maryland, 21237.
authors.forename: Michael
authors.initials: M
authors.lastname: Auerbach
authors.forename: William
authors.initials: W
authors.lastname: Strauss
authors.forename: Sarah
authors.initials: S
authors.lastname: Auerbach
authors.forename: Stella
authors.initials: S
authors.lastname: Rineer
authors.forename: Huzefa
authors.initials: H
authors.lastname: Bahrain
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy*; D018771:Arthralgia / Q000139:chemically induced / Q000209:etiology; D004334:Drug Administration Schedule; D004909:Erythrocyte Indices; D005260:Female; D052203:Ferrosoferric Oxide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007262:Infusions, Intravenous; D007501:Iron / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D063806:Myalgia / Q000139:chemically induced / Q000209:etiology; D056687:Off-Label Use; D010865:Pilot Projects; D035703:Therapies, Investigational; D014168:Transferrin / Q000032:analysis / Q000378:metabolism; D055815:Young Adult
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D014168:Transferrin; D007501:Iron; D052203:Ferrosoferric Oxide